Issued on behalf of Aleen Inc.
VANCOUVER – Equity Insider News Commentary – Healthcare is racing ahead of the rest of corporate America in AI adoption, now deploying intelligent systems 2.2 times faster than the broader economy as hospitals, diagnostics companies, and medical device makers rush to capture efficiency gains[1]. AI has moved from experimental technology to mainstream infrastructure across thousands of medical products, from imaging software and patient monitoring to surgical robotics and personalized wellness platforms[2]. This surge is creating opportunities for innovative companies at the forefront of AI-powered healthcare and wellness, including Aleen Inc. (CSE: ALEN-U), Caris Life Sciences, Inc. (NASDAQ: CAI), Certara, Inc. (NASDAQ: CERT), Philips N.V. (NYSE: PHG), and Zimmer Biomet Holdings, Inc. (NYSE: ZBH).
Analysts project the global AI in healthcare market will surge from $21.66 billion in 2025 to $110.61 billion by 2030[3], reflecting a compound annual growth rate of 38.6 percent as chronic disease prevalence and cost pressures accelerate adoption. Procurement cycles have compressed dramatically from 12 to 18 months down to under six months[4], creating favorable conditions for companies delivering proven ROI in diagnostic accuracy, workflow automation, and personalized treatment solutions as healthcare providers race to deploy production systems.
Aleen Inc. (CSE: ALEN-U), a Canadian technology company operating in the digital wellness space, has announced it is exploring new features to help users better understand their wellness information through personalized insights. The company continues to expand tools that transform submitted wellness details into insights supporting everyday well-being.
Based in Ontario, Aleen Inc. went public on the Canadian Securities Exchange in June 2025 and has developed an AI platform designed to help users understand their inputs and wellness indicators. The initiative focuses on creating an intuitive, user-friendly experience where individuals can engage with their own wellness information in meaningful ways through responsible AI-assisted interpretation.
Aleen Inc. operates in a rapidly expanding market. The global digital wellness sector is currently valued at approximately $12.87 billion in 2025 and is projected to grow to $45.65 billion by 2034, representing annual growth of 15.1%. With about 57% of consumers now using digital apps and wearable devices to monitor their well-being, Aleen Inc. is positioned to capture a portion of this expanding demand.
The Aleen AI system can be accessed in two ways. Users can visit the Aleen website for free wellness insights, which helps raise awareness and encourages active engagement with personal well-being. Businesses can integrate Aleen Inc.’s technology via its API, allowing wellness apps and digital platforms to embed the AI-powered insights into their own services. The company generates revenue through its API offerings, available through a per-call option for businesses paying only for requests used, and a monthly subscription for consistent access.
Looking ahead to 2026, Aleen Inc. has announced ambitious expansion plans. The company is preparing to launch personal user accounts that will allow individuals to securely store and organize their wellness information in one place. Additionally, the company plans to introduce smart analytics features that will help users identify patterns in their wellness data and make more informed decisions about their well-being.
To fund these initiatives, Aleen Inc. is currently seeking between $20 million and $30 million in strategic investment. The company plans to allocate 35% of these funds toward technology development, 30% toward sales and marketing efforts, and 20% for product expansion including mobile apps and specialized modules for corporate wellness programs.
The company emphasizes that its platform is designed for preliminary wellness insights only and is not intended to replace consultations with healthcare professionals. Aleen Inc. does not provide medical diagnoses and is not regulated as a medical device by the FDA or other health authorities.
With 12,643,300 common shares currently issued and outstanding, Aleen Inc. continues to build its presence in the digital wellness space under the leadership of CEO Inna Aksman.
CONTINUED… Read this and more news for Aleen Inc. at:
Caris Life Sciences, Inc. (NASDAQ: CAI) has validated TET2 clonal hematopoiesis as a promising biomarker for improved response to immune checkpoint inhibitor therapy in patients with solid tumors, leveraging its extensive clinico-genomic database of nearly 36,000 non-small cell lung cancer patients and over 25,000 colorectal cancer patients. The collaborative research, published in Cancer Cell and led by Padmanee Sharma, M.D., Ph.D. at The University of Texas MD Anderson Cancer Center, directly ties clonal hematopoiesis to therapy outcomes in solid tumors.
“These findings represent a major step forward in understanding how clonal hematopoiesis influences cancer immunology,” said Milan Radovich, Ph.D., Senior Vice President, Chief Scientific Officer at Caris. “It further demonstrates that we are only scratching the surface on the potential applications of CH, namely a novel function of CH as a predictive therapeutic biomarker that can be used to improve patient outcomes.”
The discovery positions Caris at the forefront of precision medicine innovation by demonstrating how its advanced AI and machine learning algorithms applied to large-scale, multimodal clinico-genomic data can uncover novel therapeutic biomarkers. This breakthrough suggests a future role for clonal hematopoiesis in driving therapy selection decisions for oncology patients.
Certara, Inc. (NASDAQ: CERT) has launched TFL Studio, the first cloud-native module of its Phoenix Cloud solution that cuts time to create Tables, Figures, and Listings by 50% for pharmacokinetic and pharmacodynamic scientists. The platform automates critical components of regulatory submissions and scientific publications through AI-powered workflows that eliminate manual processes and fragmented tools.
“The introduction of TFL Studio marks a pivotal moment in our mission to bring advanced, cloud-native solutions to drug discovery and development,” said William F. Feehery, CEO of Certara. “TFL Studio empowers scientists to create high-quality TFLs up to 50% faster, freeing them from the technical complexities of moving source data, coding, and manual formatting,” said Martin Snyder, President of Certara Data Sciences. “This allows them to focus on science, derive insights more quickly, and ultimately accelerate critical decision-making.”
The company will complement TFL Studio with AI PK Reports later this quarter, which leverages GenAI through its CoAuthor software to transform tables, figures, and listings into draft PK reports in minutes rather than days. TFL Studio integrates with Integral, Certara’s data repository, providing a single source of truth for PK/PD data, models, and visualizations across drug development workflows.
Philips N.V. (NYSE: PHG) has delivered strong third-quarter results with comparable sales growing 3.3% to EUR 4.3 billion, comparable order intake growth of 8%, and adjusted EBITA margin expanding 50 basis points to 12.3% of sales. The company’s AI-powered innovations drove sustained momentum in North America, with free cash flow increasing to EUR 172 million as margin expansion was achieved through increased sales, favorable mix effects, and productivity improvements.
“In this quarter we maintained our momentum, with AI-powered innovations and long-term partnerships making a real difference for patients and consumers,” said Roy Jakobs, CEO of Philips. “We drove strong order intake and accelerated sales growth, with sustained strength in North America. We expanded margin through innovation, focused execution and cost discipline, remaining firmly on-track as we navigate an uncertain macro environment including tariffs.”
Philips launched several breakthrough technologies in the quarter, including the Lumea IPL hair removal system in the US, advanced radiation therapy solutions including Rembra RT and Areta RT CT scanners, and Transcend Plus cardiovascular ultrasound systems featuring 26 FDA-cleared AI applications—the most in the industry. The company signed long-term Enterprise Monitoring as a Service partnerships with leading US health systems including Hoag in Orange County and Rady Children’s Hospital in San Diego, while reiterating its full-year 2025 outlook with adjusted EBITA margin now expected toward the upper end of the 11.3%-11.8% range.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) has showcased bold robotics innovations at the 2025 American Association of Hip and Knee Surgeons annual meeting, featuring its comprehensive portfolio including the recently acquired mBôs™ TKA System, a CT-based semi-autonomous total knee arthroplasty robotic technology that received FDA 510(k) clearance. The company’s booth prominently displayed its ecosystem of robotics, digital platforms, and AI solutions including ROSA Knee with OptimiZe™, TMINI Miniature Robotic System, and ZBEdge Analytics—a data platform delivering intra-operative insights directly via smartphone.
“Orthopedics is at a pivotal moment,” said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. “As the population ages and expectations rise, patients are demanding more: less disruption, faster recovery and care that fits their lives. Surgeons need solutions that match this urgency, and that’s why we’ve engineered next-generation hip and knee implants and curated an ecosystem of robotics, digital platforms and AI. This isn’t incremental innovation — it’s the most ambitious innovation cycle in our company’s history, positioning Zimmer Biomet to deliver the industry’s most comprehensive and adaptable suite of orthopedic robotics and navigation technologies designed to elevate surgical precision and transform patient outcomes.”
The company’s innovation portfolio includes Persona IQ The Smart Knee, a first-to-world smart knee implant capturing patient-specific gait and range of motion metrics directly from the knee, and OrthoGrid Hip AI, an AI-powered fluoroscopy-based technology providing intuitive intra-operative tools for component positioning. Zimmer Biomet also showcased its digital care management platform mymobility and the Oxford Cementless Partial Knee, the only FDA-approved mobile cementless partial knee implant in the US.
Article Sources: https://equity-insider.com/2025/10/31/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/
CONTACT:
Equity Insider
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity-Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Aleen Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Aleen Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Aleen Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Aleen Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Aleen’s solutions operate within the wellness domain and are not subject to FDA or Health Canada approval.
—
SOURCES:
- https://hitconsultant.net/2025/10/22/healthcare-ai-adoption-is-2-2x-faster-than-the-broader-economy/
- https://intuitionlabs.ai/articles/ai-medical-devices-regulation-2025
- https://www.marketsandmarkets.com/PressReleases/artificial-intelligence-healthcare.asp
- https://menlovc.com/perspective/2025-the-state-of-ai-in-healthcare/
